Amiodarone-induced QT prolongation in a newly transplanted heart associated with recurrent ventricular fibrillation.
Anti-arrhythmic drugs such as amiodarone have the potential to prolong QT intervals, which can result in torsades de point arrhythmia. It is unknown whether amiodarone, given to a recipient prior to cardiac transplantation, can cause arrhythmia in a newly transplanted donor heart. We report on a case of a 71-year-old male patient who had received intravenous and oral amiodarone prior to transplantation, which was associated with QT prolongation in the transplanted heart after re-exposure to the drug during subsequent episodes of ventricular fibrillation. An ICD was implanted, which has not been described that soon after cardiac transplantation. Amiodarone, given to a recipient, might cause QT prolongation in a donor heart after transplantation, possibly due to its long half-life and increased bioavailability caused by interaction with immunosuppressive drugs.
Schwarz
E R
ER
Cedars Sinai Heart Institute, Division of Cardiology, Division of Cardiothoracic Surgery, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, and University of California Los Angeles, (UCLA), Los Angeles, USA.
Czer
L S
LS
Simsir
S A
SA
Kass
R M
RM
Trento
A
A
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects*; D006333:Heart Failure / Q000150:complications / Q000601:surgery; D016027:Heart Transplantation; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D008297:Male; D012008:Recurrence; D014693:Ventricular Fibrillation / Q000150:complications / Q000503:physiopathology / Q000628:therapy*
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone